MindBio Therapeutics (FRA:WF60) Cash Flow for Dividends: €0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:WF60 MindBio Therapeutics Corp FRA:WF60
37 GF Score
Price €0.13
! 1 Warning Sign
View Full Analysis

What is MindBio Therapeutics Cash Flow for Dividends?

MindBio Therapeutics FRA:WF60 37 Cash Flow for Dividends is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:WF60 with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

MindBio Therapeutics's cash flow for dividends for the three months ended in Mar. 2026 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

MindBio Therapeutics Cash Flow for Dividends Related Terms

MindBio Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for MindBio Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindBio Therapeutics Cash Flow for Dividends Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow for Dividends
0.00 -0.52 0.00 0.00 0.00

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:WF60
37GF Score
MindBio Therapeutics Corp FRA:WF60
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindBio Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
MindBio Therapeutics (FRA:WF60) has a Cash Flow for Dividends of €0.00 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for MindBio Therapeutics and its competitors.
Is MindBio Therapeutics' Cash Flow for Dividends too high?
MindBio Therapeutics' current Cash Flow for Dividends is €0.00 Mil. Overall, MindBio Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
MindBio Therapeutics' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for MindBio Therapeutics and its competitors. MindBio Therapeutics's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (FRA:WF60) has a current Cash Flow for Dividends of €0.00 Mil. The current Cash Flow for Dividends is €0.00 Mil. MindBio Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For MindBio Therapeutics (FRA:WF60), the current Cash Flow for Dividends is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindBio Therapeutics Business Description

Other Exchanges MBIO:Canada
Address 91-97 William Steet, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
37GF Score

Get the complete analysis for FRA:WF60

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price